Factors associated with event-free survival in Chinese patients with Takayasu's arteritis.
Yu WeiCheng ZhaoJun LiangZiyi JinBingzhu HuaHong WangHuayong ZhangXuebing FengPublished in: Clinical rheumatology (2020)
Even with vigorous therapy, a large proportion of TA patients may present adverse outcomes along with the development of disease. Low-dose CTX treatment is helpful for a better prognosis. Key Points • The prognosis of Takayasu's arteritis is still poor. • Application of low-dose cyclophosphamide in high-risk patients helps to improve the outcome. • Abnormal lipid profiles may contribute to the development of this disease, which also deserves attention.